Sign In
Buy IOVA
$3.79
-0.310 (-7.56%)
At Close: Jun 03, 2026
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
05:00pm, Friday, 21'st Jun 2024
SAN CARLOS, Calif., June 21, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and deli
3 Top Penny Stocks to Skyrocket Your Wealth in 2024
06:36am, Friday, 21'st Jun 2024
Many people overlook penny stocks due to the inherent risk of investing in them. The stocks are infamous for producing poor results and being too hard to trade profitably.
The Case for Buying Iovance Biotherapeutics Stock Just Got Even Better. Here's Why
10:15am, Monday, 10'th Jun 2024
Iovance Biotherapeutics makes a cell therapy called Amtagvi for melanoma. Amtagvi isn't currently approved as a first-line treatment.
Iovance Biotherapeutics to Present at Upcoming Conferences and Events
04:01pm, Friday, 24'th May 2024
SAN CARLOS, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infi
Iovance (IOVA) Up 5% on Updated Data From Melanoma Study
12:20pm, Friday, 24'th May 2024
Iovance (IOVA) shares updated data from a mid-stage study, which showed that treatment with its combination therapy achieved an objective response rate of 65% in frontline advanced melanoma.
Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting
05:00pm, Thursday, 23'rd May 2024
Lifileucel TIL Cell Therapy in Combination with Pembrolizumab Demonstrates Deep, Durable Responses in Frontline Advanced Melanoma Patients in IOV-COM-202 Clinical Study
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
06:40am, Wednesday, 22'nd May 2024
Indexes are extending bull market gains, reaching new records. It's not too late to get in on the action -- history suggests this bull market could have much farther to go.
Panagora Asset Management Inc. Has $2.82 Million Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
07:14am, Monday, 20'th May 2024
Panagora Asset Management Inc. boosted its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 3.7% during the fourth quarter, according to the company in its most re
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
05:15pm, Friday, 17'th May 2024
SAN CARLOS, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and deliv
4 Small-Cap Value Stocks That Could Go Parabolic
09:30am, Thursday, 16'th May 2024
Small-cap stocks have historically responded positively to interest-rate cuts. These four small-cap equities may be poised for a bull run once the Fed eventually slashes rates.
The 3 Most Undervalued Biotech Stocks to Buy in May 2024
10:00am, Saturday, 11'th May 2024
The biotech sector holds some of the most promising and popular stocks on the market. With the promise of breakthrough treatments that generate billions of dollars annually, investors always look for
Why Iovance Stock Is Down 18% Today
02:03pm, Friday, 10'th May 2024
Iovance Biotherapeutics' first-quarter sales fell short of estimates. The quarter in question, however, isn't a fair reflection of the business the company's intending to build.
Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates
12:01pm, Friday, 10'th May 2024
Iovance (IOVA) reports mixed first-quarter results. Shares gain on encouraging initial demand for the recently-approved melanoma drug Amtagvi in the United States.
Iovance Biotherapeutics, Inc. (IOVA) Q1 2024 Earnings Call Transcript
08:40pm, Thursday, 09'th May 2024
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA ) Q1 2024 Results Conference Call May 9, 2024 4:30 PM ET Company Participants Sara Pellegrino - Senior Vice President, Investor Relations & Corporate Communi
Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
04:01pm, Thursday, 09'th May 2024
Strong Momentum for Amtagvi™ (Lifileucel) U.S. Launch Following U.S. Food and Drug Administration (FDA) Approval
